Nicox S.A.
Ophthalmology company developing therapies based on a nitric oxide-donating platform.
COX | PA
Overview
Corporate Details
- ISIN(s):
- FR0013018124 (+6 more)
- LEI:
- 969500EZGEO9W4JXR353
- Country:
- France
- Address:
- SOPHIA, 06410 BIOT
- Website:
- https://www.nicox.com/
Description
Nicox S.A. is an international ophthalmology company focused on the research and development of innovative therapeutic solutions to maintain vision and improve ocular health. The company's lead product candidate is NCX 470, a novel nitric oxide (NO)-donating bimatoprost analog in late-stage clinical development for the lowering of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Nicox's pipeline is based on its proprietary NO-donating research platform. The company has also developed two approved ophthalmic products: VYZULTA® (latanoprostene bunod ophthalmic solution), licensed exclusively to Bausch + Lomb, and ZERVIATE® (cetirizine ophthalmic solution), licensed to various partners for commercialization.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-06-06 07:30 |
Nicox: Notice of the Ordinary and Extraordinary Shareholders’ Meeting on June 2…
|
English | 175.2 KB | ||
| 2025-05-27 07:30 |
Nicox Announces up to €3 million in Milestone Payments from Kowa in 2025 as NCX…
|
English | 179.6 KB | ||
| 2025-05-27 07:30 |
Nicox annonce jusqu’à 3 millions d’euros de paiements d’étapes de la part de Ko…
|
French | 183.6 KB | ||
| 2025-05-14 07:30 |
Nicox annonce les résultats de l’étude exploratoire de phase 3b Whistler dans l…
|
French | 199.5 KB | ||
| 2025-05-14 07:30 |
Nicox Announces Results of the Exploratory Whistler Phase 3b Glaucoma Trial
|
English | 184.4 KB | ||
| 2025-04-30 07:30 |
Nicox Provides Full Year 2024 Financial Results
|
English | 181.9 KB | ||
| 2025-04-30 07:30 |
Nicox : Résultats financiers de l’année 2024
|
French | 180.4 KB | ||
| 2025-03-19 07:30 |
Nicox Announces Last Patient Completes Final Visit in NCX 470 Phase 3b Whistler…
|
English | 218.6 KB | ||
| 2025-03-19 07:30 |
Nicoxannonce que la visite finale du dernier patient a été effectuée dans l’étu…
|
French | 237.5 KB | ||
| 2025-03-06 07:30 |
Nicox prolonge l’horizon de sa trésorerie jusqu’au quatrième trimestre 2025
|
French | 297.6 KB | ||
| 2025-03-06 07:30 |
Nicox Extends Cash Runway into Q4 2025
|
English | 239.3 KB | ||
| 2025-03-03 07:30 |
Nicox Presents New Analysis from the NCX 470 Mont Blanc Trial and Provides Deve…
|
English | 232.7 KB | ||
| 2025-03-03 07:30 |
Nicox présente une nouvelle analyse de l'étude NCX 470 Mont Blanc et fournit un…
|
French | 265.2 KB | ||
| 2025-01-22 07:30 |
Nicox confirme son éligibilité au PEA-PME
|
French | 215.6 KB | ||
| 2025-01-21 07:30 |
Nicox : Point d’activité et résumé financier du quatrième trimestre 2024
|
French | 256.3 KB |
Automate Your Workflow. Get a real-time feed of all Nicox S.A. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Nicox S.A.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Nicox S.A. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
